Cancer Letters
Volume 228, Issue 1 , Pages 29-35 , 18 October 2005

Functional implication of p73 protein stability in neuronal cell survival and death

  • Toshinori Ozaki

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • ,
  • Mitsuchika Hosoda

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • Department of General Surgery, Hokkaido University School of Medicine, Sapporo 060-8638, Japan
    • ,
  • Kou Miyazaki

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • ,
  • Syunji Hayashi

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • Department of General Surgery, Hokkaido University School of Medicine, Sapporo 060-8638, Japan
    • ,
  • Ken-ichi Watanabe

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • Department of General Surgery, Hokkaido University School of Medicine, Sapporo 060-8638, Japan
    • ,
  • Takahito Nakagawa

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • Department of General Surgery, Hokkaido University School of Medicine, Sapporo 060-8638, Japan
    • ,
  • Akira Nakagawara

      Affiliations

    • Division of Biochemistry, Chiba Cancer Center Research Institute, 666-2 Nitona, Chuoh-ku, Chiba 260-8717, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 43 264 5431; fax: +81 43 265 4459.

Received 26 November 2004 ,Accepted 2 December 2004.

References 

  1. Kaghad M, Bonnet H, Yang A, Creancier L, Biscan JC, Valent A, et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 1997;90:809–819
  2. Yang A, Kaghad M, Wang Y, Gillett E, Fleming MD, Dotsch V, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol. Cell. 1998;2:305–316
  3. Melino G, De Laurenzi V, Vousden KH. p73: friend or foe in tumorigenesis. Nat. Rev. Cancer. 2002;2:605–615
  4. Ikawa S, Nakagawara A, Ikawa Y. p53 family genes: structural comparison, expression and mutation. Cell Death Differ. 1999;6:1154–1161
  5. Yang A, Walker N, Bronson R, Kaghad M, Oosterwegel M, Bonnin J, et al. Caput, p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature. 2000;404:99–103
  6. Flores ER, Tsai KY, Crowley D, Sengupta S, Yang A, McKeon F, et al. p63 and p73 are required for p53-dependent apoptosis in response to DNA damage. Nature. 2002;416:560–564
  7. Jost CA, Marin MC, Kaelin WG. p73 is a simian p53-related protein that can induce apoptosis. Nature. 1997;389:191–194
  8. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell Biol. 1999;19:3257–3266
  9. Moll UM, LaQuaglia M, Benard J, Riou G. Wild type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. Proc. Natl Acad. Sci. USA. 1995;92:4407–4411
  10. Stiewe T, Zimmermann S, Frilling A, Esche H, Putzer BM. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res. 2002;62:3598–3602
  11. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science. 2000;289:304–306
  12. Casciano I, Mazzocco K, Boni L, Pagnan G, Banelli B, Allemanni G, et al. Expression of ΔNp73 is a molecular marker for adverse outcome in neuroblastoma patients. Cell Death Differ. 2002;9:246–251
  13. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, et al. ΔNp73 a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 2002;196:765–780
  14. Grob TJ, Novak U, Maisse C, Barcaroli D, Luthi AU, Pimia F, et al. Human ΔNp73 regulates a dominant negative feedback loop for TAp73 and p53. Cell Death Differ. 2001;8:1213–1223
  15. Nakagawa T, Takahashi M, Ozaki T, Watanabe K, Todo S, Mizuguchi H, et al. Autoinhibitory regulation of p73 by ΔNp73 to modulate cell survival and death through a p73-specific target element within the ΔNp73 promoter. Mol. Cell Biol. 2002;22:2575–2585
  16. Irwin MS, Kondo K, Marin MC, Cheng LS, Hahn WC, Kaelin WG. Chemosensitivity linked to p73 function. Cancer Cell. 2003;3:403–410
  17. Balint E, Bates S, Vousden KH. Mdm2 binds p73α without targeting degradation. Oncogene. 1999;18:3923–3929
  18. Lee CW, La Thangue NB. Promoter specificity and stability control of the p53-related protein p73. Oncogene. 1999;18:4171–4181
  19. Gong J, Costanzo A, Yang HG, Melino G, Kaelin WG, Levrero M, et al. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 1999;399:806–809
  20. Agami R, Blandino G, Oren M, Shaul Y. Interaction of c-Abl and p73α and their collaboration to induce apoptosis. Nature. 1999;399:809–813
  21. Yuan ZM, Shioya H, Ishiko T, Sun X, Gu J, Huang YY, et al. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 1999;399:814–817
  22. Ben-Yehoyada M, Ben-Dor I, Shaul Y. c-Abl tyrosine kinase selectively regulates p73 nuclear matrix association. J. Biol. Chem. 2003;278:34475–34482
  23. Ren J, Datta R, Shioya H, Li Y, Oki E, Biedermann V, et al. p73β is regulated by protein kinase Cδ catalytic fragment generated in the apoptotic response to DNA damage. J. Biol. Chem. 2002;277:33758–33765
  24. Gonzalez S, Prives C, Cordon-Cardo C. p73α regulation by Chk1 in response to DNA damage. Mol. Cell. Biol. 2003;23:8161–8171
  25. Gaiddon C, Lokshin M, Gross I, Levasseur D, Taya Y, Loeffler JP, et al. Cyclin-dependent kinases phosphorylate p73 at threonine 86 in a cell cycle-dependent manner and negatively regulate p73. J. Biol. Chem. 2003;278:27421–27431
  26. Zeng X, Li X, Miller A, Yuan Z, Yuan W, Kwok RP, et al. The N-terminal domain of p73 interacts with the CH1 domain of p300/CBP binding protein and mediates transcriptional and apoptosis. Mol. Cell. Biol. 2001;20:1299–1310
  27. Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell. 2002;9:175–186
  28. Mantovani F, Piazza S, Gostissa M, Strano S, Zacchi P, Mantovani R, et al. Pin1 links the activities of c-Abl and p300 in regulating p73 function. Mol. Cell. 2004;14:625–636
  29. Kramer S, Ozaki T, Miyazaki K, Kato C, Hanamoto T, Nakagawara A. Protein stability and function of p73 are modulated by a physical interaction with RanBPM in mammalian cultured cells. Oncogene. 2005;27:938–944
  30. Bernassola F, Salomoni P, Oberst A, Di Como CJ, Pagano M, Melino G, et al. Ubiquitin-dependent degradation of p73 is inhibited by PML. J. Exp. Med. 2004;199:1545–1557
  31. Wu L, Zhu H, Nie L, Maki CG. A link between p73 transcriptional activity and p73 degradation. Oncogene. 2004;23:4032–4036
  32. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature. 1997;387:296–299
  33. Kubbutat MHG, Jones SN, Vousden KH. Regulation of p53 stability by mdm2. Nature. 1997;387:299–303
  34. Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. Fed. Eur. Biochem. Soc. Lett. 1997;420:25–27
  35. Zeng X, Chen L, Jost CA, Maya R, Keller D, Wang X, et al. MDM2 suppresses p73 function without promoting p73 degradation. Mol. Cell. Biol. 1999;19:3257–3266
  36. Balint E, Bates S, Vousden KH. Mdm2 binds p73α without targeting degradation. Oncogene. 1999;18:3923–3929
  37. Calabro V, Mansueto G, Parisi T, Vivo M, Calogero RA, La Mantia G. The human MDM2 oncoprotein increases the transcriptional activity and the protein level of the p53 homolog p63. J. Biol. Chem. 2002;277:2674–2681
  38. Leng RP, Lin Y, Ma W, Wu H, Lemmers B, Chung S, et al. Pirh2, a p53-induced ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003;112:779–791
  39. Toh WH, Siddique MM, Boominathan L, Lin KW, Sabapathy K. c-Jun regulates the stability and activity of the p53 homologue, p73. J. Biol. Chem. 2004;22:44713–44722
  40. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. Eur. Mol. Biol. Org. J. 1994;13:4816–4822
  41. Ohtsuka T, Ryu H, Minamishima YA, Ryo A, Lee SW. Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene. 2003;22:1678–1687
  42. Marin MC, Jost CA, Irwin M, Decaprio JA, Caput D, Kaelin WG. Viral oncoproteins discriminate between p53 and the p53 homolog p73. Mol. Cell. Biol. 1998;18:6316–6324
  43. Lemasson I, Nyborg JK. Human T-cell leukemia virus type I Tax repression of p73β is mediated through competition for the C/H1 domain of CBP. J. Biol. Chem. 2001;276:15720–15727
  44. Grossman SR, Deato ME, Brignone C, Chan HM, Kung AL, Tagami H, et al. Polyubiquitination of p53 by a ubiquitin ligase activity of p300. Science. 2003;300:342–344
  45. Ohira M, Kageyama H, Mihara M, Furuta S, Machida T, Shishikura T, et al. Identification and characterization of a 500-kb homozygously deleted region at 1p36.2-p36.3 in a neuroblastoma cell line. Oncogene. 2000;19:4302–4307
  46. Koegl M, Hoppe T, Schlenker S, Ulrich HD, Mayer TU, Jentsch S. A novel ubiquitination factor, E4, is involved in multiubiquitin chain assembly. Cell. 1999;96:635–644
  47. Hatakeyama S, Yada M, Matsumoto M, Ishida N, Nakayama KI. U box proteins as a new family of ubiquitin-protein ligases. J. Biol. Chem. 2001;276:33111–33120
  48. Mahoney JA, Odin JA, White SM, Shaffer D, Koff A, Casciola-Rosen L. The human homologue of the yeast polyubiquitination factor Ufd2p is cleaved by caspase 6 and granzyme B during apoptosis. Biochem. J. 2002;361:587–595

PII: S0304-3835(05)00323-X

doi: 10.1016/j.canlet.2004.12.050

Cancer Letters
Volume 228, Issue 1 , Pages 29-35 , 18 October 2005

Article Tools

* Image Usage & Resolution